Motif Bio Competitors and Similar CompaniesClear all
Motif Bio's competitors and similar companies include NIOX, Durect, Array BioPharma and Sucampo Pharmaceuticals.
 Motif Bio Motif BioSciences, a population genetics company, focuses on the genetic causes of major diseases usinghuman genetic data from individuals. |  NIOX NIOX (formerly Circassia) is a specialty biopharmaceutical company focused on developing novel immunotherapies |  Durect DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases. |  Array BioPharma Array BioPharma is focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. |  Sucampo Pharmaceuticals Sucampo is a global biopharmaceutical company focused on the development and commercialization of medicines based on prostones, to meet the major unmet medical needs of patients on a global basis. | |
Founding Date | Founding Date N/A | Founding Date 2006 | Founding Date N/A | Founding Date 1998 | Founding Date 1996 |
Type | Type Public | Type Public | Type Public | Type Subsidiary | Type Subsidiary |
Tags | |||||
Locations | Locations London, GB HQ New York, US | Locations Morrisville, US HQ Bad Homburg Vor Der Höhe, DE Uppsala, SE Morrisville, US | Locations Cupertino, US HQ | Locations Boulder, US HQ Chicago, US Detroit, US Houston, US Miami, US New York, US Phoenix, US | Locations Rockville, US HQ Chiyoda, JP Chuo Ward, JP Kita Ward, JP Sanda Shi, JP Zug, CH Milton, GB |
Employees | Employees 6 | Employees 91 | Employees 902% increase | Employees 110 | Employees 37 |
Valuation ($) | Valuation ($) 4.6 m | Valuation ($) 340.9 m | Valuation ($) 45.3 m | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) £48.7m (FY, 2025) | Revenue (est.) $2m (FY, 2024) | Revenue (est.) $173.8m (FY, 2018) | Revenue (est.) $230.1m (FY, 2016) |
Cost of goods | Cost of goods N/A | Cost of goods £11.1m (FY, 2025) | Cost of goods $78k (FY, 2024) | Cost of goods $59.4m (FY, 2018) | Cost of goods $76m (FY, 2016) |
Gross profit | Gross profit N/A | Gross profit £38.2m (FY, 2025) | Gross profit $2m (FY, 2024) | Gross profit $114.4m (FY, 2018) | Gross profit $154.1m (FY, 2016) |
Net income | Net income (£10.7m) (FY, 2018) | Net income £7m (FY, 2025) | Net income ($8.3m) (FY, 2024) | Net income ($147.7m) (FY, 2018) | Net income $18.5m (FY, 2016) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 122.8m | Total funding raised $ 20m | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
NIOX
HQ
Morrisville, US
Employees
91
NIOX (formerly Circassia) is a specialty biopharmaceutical company focused on developing novel immunotherapies
View companyDurect
HQ
Cupertino, US
Employees
90↑ 2% increase
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases.
View companyArray BioPharma
HQ
Boulder, US
Array BioPharma is focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.
View companySucampo Pharmaceuticals
HQ
Rockville, US
Sucampo is a global biopharmaceutical company focused on the development and commercialization of medicines based on prostones, to meet the major unmet medical needs of patients on a global basis.
View company